CN1305491A - 晶体形式的1S-[1a(2S ,3R ),9a]-6,10-二氧代-N-(2-乙氧基-5-氧代-四氢-3-呋喃基)-9[[1-异喹啉基羰基)氨基],八氢-6H-哒嗪并[1,2-A][1,2]二氮杂䓬-1-甲酰胺 - Google Patents
晶体形式的1S-[1a(2S ,3R ),9a]-6,10-二氧代-N-(2-乙氧基-5-氧代-四氢-3-呋喃基)-9[[1-异喹啉基羰基)氨基],八氢-6H-哒嗪并[1,2-A][1,2]二氮杂䓬-1-甲酰胺 Download PDFInfo
- Publication number
- CN1305491A CN1305491A CN99807145A CN99807145A CN1305491A CN 1305491 A CN1305491 A CN 1305491A CN 99807145 A CN99807145 A CN 99807145A CN 99807145 A CN99807145 A CN 99807145A CN 1305491 A CN1305491 A CN 1305491A
- Authority
- CN
- China
- Prior art keywords
- type
- dioxo
- oxo
- carbonyl
- isoquinolyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- -1 1-isoquinolyl Chemical group 0.000 title claims abstract description 19
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 title claims abstract description 16
- AUHBCNJHXCDLMK-UHFFFAOYSA-N diazepine-1-carboxamide Chemical compound NC(=O)N1C=CC=CC=N1 AUHBCNJHXCDLMK-UHFFFAOYSA-N 0.000 title 1
- 238000000034 method Methods 0.000 claims abstract description 15
- 239000003814 drug Substances 0.000 claims abstract description 8
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 7
- 239000013078 crystal Substances 0.000 claims description 18
- 238000002425 crystallisation Methods 0.000 claims description 14
- 230000008025 crystallization Effects 0.000 claims description 14
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 14
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Natural products CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims description 11
- 239000000203 mixture Substances 0.000 claims description 11
- 230000036571 hydration Effects 0.000 claims description 10
- 238000006703 hydration reaction Methods 0.000 claims description 10
- 238000002360 preparation method Methods 0.000 claims description 10
- 238000010521 absorption reaction Methods 0.000 claims description 8
- 238000002329 infrared spectrum Methods 0.000 claims description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 7
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 7
- 239000002904 solvent Substances 0.000 claims description 6
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 claims description 5
- 238000002844 melting Methods 0.000 claims description 5
- 230000008018 melting Effects 0.000 claims description 5
- 102000000589 Interleukin-1 Human genes 0.000 claims description 4
- 108010002352 Interleukin-1 Proteins 0.000 claims description 4
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 4
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 claims description 4
- 230000018044 dehydration Effects 0.000 claims description 3
- 238000006297 dehydration reaction Methods 0.000 claims description 3
- 239000003085 diluting agent Substances 0.000 claims description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 2
- 239000003960 organic solvent Substances 0.000 claims description 2
- 238000002835 absorbance Methods 0.000 claims 2
- 125000003158 alcohol group Chemical group 0.000 claims 1
- 125000001033 ether group Chemical group 0.000 claims 1
- 125000003944 tolyl group Chemical group 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 description 26
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 11
- 238000000634 powder X-ray diffraction Methods 0.000 description 9
- 238000000113 differential scanning calorimetry Methods 0.000 description 6
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 239000012429 reaction media Substances 0.000 description 5
- 238000001035 drying Methods 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- 238000005033 Fourier transform infrared spectroscopy Methods 0.000 description 2
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000000704 physical effect Effects 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 1
- LAOZSCRCYVBSJA-UHFFFAOYSA-N 5,5-dimethyl-1,3-diazinane-2,4,6-trione Chemical compound CC1(C)C(=O)NC(=O)NC1=O LAOZSCRCYVBSJA-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 235000006491 Acacia senegal Nutrition 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 239000001828 Gelatine Substances 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 240000006474 Theobroma bicolor Species 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 239000004411 aluminium Substances 0.000 description 1
- 229940059260 amidate Drugs 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000008365 aqueous carrier Substances 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 229960000935 dehydrated alcohol Drugs 0.000 description 1
- 229910001873 dinitrogen Inorganic materials 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 229960004756 ethanol Drugs 0.000 description 1
- NPUKDXXFDDZOKR-LLVKDONJSA-N etomidate Chemical compound CCOC(=O)C1=CN=CN1[C@H](C)C1=CC=CC=C1 NPUKDXXFDDZOKR-LLVKDONJSA-N 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- AWJUIBRHMBBTKR-UHFFFAOYSA-N iso-quinoline Natural products C1=NC=CC2=CC=CC=C21 AWJUIBRHMBBTKR-UHFFFAOYSA-N 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 239000012299 nitrogen atmosphere Substances 0.000 description 1
- 229910052763 palladium Inorganic materials 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 238000005220 pharmaceutical analysis Methods 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 238000010926 purge Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000007614 solvation Methods 0.000 description 1
- 125000006850 spacer group Chemical group 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 238000004441 surface measurement Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical class C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 1
- 239000006216 vaginal suppository Substances 0.000 description 1
- 229940120293 vaginal suppository Drugs 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
- C07K5/0202—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-X-X-C(=0)-, X being an optionally substituted carbon atom or a heteroatom, e.g. beta-amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Biomedical Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Crystallography & Structural Chemistry (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Peptides Or Proteins (AREA)
Abstract
本发明涉及新的晶体形式的1S-[1α(2S<sup>*</sup>,3R<sup>*</sup>),9α]-6,10-二氧代-N-(2-乙氧基-5-氧代-四氢-3-呋喃基)-9-[[(1-异喹啉基)羰基]氨基]八氢-6H-哒嗪并[1,2-a][1,2]二氮杂䓬-1-甲酰胺,无水的(A型)和水合的(B型),它们的制备方法,作为药物的应用和含有它们的药物组合物。
Description
本发明的对象是两种新的晶体形式的1S-[1α(2S*,3R*),9α]-6,10-二氧代-N-(2-乙氧基-5-氧代-四氢-3-呋喃基)-9-[[(1-异喹啉基)羰基]氨基]八氢-6H-哒嗪并[1,2-a][1,2]二氮杂-1-甲酰胺(无水的或水合的),它们的制备方法和含有它们的药物组合物。
专利申请WO9722619描述了作为白细胞介素-1β转化酶的抑制剂的1S-[1α(2S*,3R*),9α]-6,10-二氧代-N-(2-乙氧基-5-氧代-四氢-3-呋喃基)-9-[[(1-异喹啉基)羰基]氨基]八氢-6H-哒嗪并[1,2-a][1,2]二氮杂-1-甲酰胺及其可药用的盐(产物412f:化合物Ⅰ):
该申请(WO9722619)中提到和制备的化合物(Ⅰ)是无定形的。它的主要缺点是吸湿性。
化合物(Ⅰ)是以下述方式制备的:(1S,9S)9-(异喹啉-1-酰氨基)-6,10-二氧代-1,2,3,4,7,8,9,10-八氢-6H-哒嗪并-[1,2-a][1,2]-二氮杂-1-羧酸和(3S,2S)3-烯丙氧基羰基氨基-2-苄氧基-5-氧代四氢呋喃在二甲基巴比妥酸、四(三苯膦)合钯、1-羟基苯并三唑及1-(3-二甲基氨基丙基)-3-乙基碳化二亚胺盐酸盐存在下,于二氯甲烷、二甲基甲酰胺或这两种溶剂的混合物中进行酰胺化反应。产物用层析法(乙酸乙酯/二氯甲烷)纯化,以得到无定形化合物(Ⅰ)。
本发明的目的是找到一种或多种没有无定形化合物的缺点的新的晶体形式。
固体形式,特别是药物产物,可以具有一种以上的晶型,这称作同质多晶现象。
相同分子的多晶型形式,一般会显示不同的物理性质,例如溶解度、吸湿性和稳定性。应该指出,目前还不存在使某种多晶型物得以形成的方法,也无法预测它们的物理性质。
获得具有治疗活性的分子的新的多晶型对于药物工业有很大意义,尤其是从它们的工业规模制备、它们在药物组合物中的应用、寻求更好的稳定性和更好的生物利用度来看。(Byrn,S.R.,药物的固态化学(Solid-State Chemistry of Drugs),New York,Academ.Press(1982);Kuhnert-Brandstatter,M,药物分析中的热显微术(Thermomicroscopy in the Analysis of pharmaceuticais),New York,Pergamon Press(1971);J.Halebian等,药物科学杂志(J.Pharm.Science)(1969)58(8),911;J.Halebian等,药物科学杂志(J.Pharm.Science)(1975)64(8),1269-1288)。
多晶型意味着一种结晶分子的所有的非溶剂化形式,而假多晶型是指所有的溶剂化形式。
分析晶型的方法如下:
热行为:用DSC(示差扫描量热法)测定。将2-5mg待测物质称量到一只透气密封的铝质小皿中。进行分析时用氮气吹洗,以20℃/分的升湿速度由25℃升至350℃。
IR(红外),待测物质分散在液体石蜡油中。在傅里叶变换红外(FTIR)分光光度计上从4000到600cm-1进行分析。
XR(粉末X射线衍射):待测物质分布在玻璃样品座的间格里。进行分析时由2°至38°(2θ)扫描,每步0.02°,计数1秒钟。X射线源为铜靶管(45KV,30mA)。
申请人揭示了两种新的晶体形式(A型和B型)。A型是无水的,B型是水合的。晶型A除了上述优点之外,还没有吸湿性(见以下的试验)。
因此,本发明的对象首先是一种新的晶体形式的无水1S-[1α(2S*,3R*),9α]-6,10-二氧代-N-(2-乙氧基-5-氧代-四氢-3-呋喃基)-9-[[(1-异喹啉基)羰基]氨基]八氢-6H-哒嗪并[1,2-a][1,2]二氮杂-1-甲酰胺,它被称为A型。这种A型具有以下特点:
晶系:三斜晶系
a():8.02;b():9.21;c()17.70;α(度):91.38;β(度):93.62;γ(度):90.43;空间群P1;Z2。
本发明的另一对象是一种新的晶体形式的水合1S-[1α(2S*,3R*),9α]-6,10-二氧代-N-(2-乙氧基-5-氧代-四氢-3-呋喃基)-9-[[(1-异喹啉基)羰基]氨基]八氢-6H-哒嗪并[1,2-a][1,2]二氮杂-1-甲酰胺,它被称作B型。
A型有以下特征:
按下述方法之一制备的式(Ⅰ)的无水化合物具有特定的晶型(A型)。在图1A(DSC)、2A(IR)和3A(XR)中描述了其物理特征。
DSC:吸热的熔融峰,自168℃开始。
IR(Nujol,cm-1):3253;1789;1702;1681;1644
XR(d,):17.73;8.87;8.11;7.50;7.17;6.31;6.09;5.81
B型有以下特征:
按下述方法之一制备的式(Ⅰ)的水合化合物具有特定的晶型(B型)。在图1B(DSC)、2B(IR)和3B(XR)中描述了其物理特征。
DSC:50-110℃和110-130℃的吸热脱水峰。观察到由162℃开始的吸热熔融峰。
IR(Nujol,cm-1):3569;3447;3322;1778;1682;1660
XR(d,):11.34;10.80;10.06;7.59;7.16;6.71;6.41;6.11;5.44。
因此,本发明的一个对象是如上定义的A型化合物,它具有至少一个以下特征,优选具有所有以下特征:
a)自168℃开始的吸热熔融峰,
b)红外光谱在大约以下位置具有特征吸收峰(Nujol,cm-1):3253;1789;1702;1681;1644,
c)XR衍射图的特征点阵间距(d,)等于:17.73;8.87;8.11;7.50;7.17;6.31;6.09;5.81。
本发明的更具体的对象是如上定义的A型化合物,它具有基本上与图2A相同的红外光谱和基本上与图3A相同的X射线衍射图。
本发明的另一对象是如上定义的B型化合物,它具有至少一个以下特征,优选具有所有以下特征:
a)50-110℃和110-130℃的吸热脱水峰,和自162℃开始的吸热熔融峰,
b)红外光谱在大约以下位置具有特征吸收峰(Nujol,cm-1):3569;3447;3322;1778;1682;1660,
c)XR衍射图的特征点阵间距(d,)等于:11.34;10.80;10.06;7.59;7.16;6.71;6.41;6.11;5.44。
本发明的另一个更具体的对象是如上定义的B型化合物,它具有与图2B基本相同的红外光谱和与图3B基本相同的XR衍射图。
本发明的对象还包括一种制备A型或B型晶体的方法,其特征在于,将按照上述方法得到的无定形化合物(Ⅰ)溶于有机溶剂或其混合物中,尤其是在室温下溶解,结晶后得到预期的A型或B型晶体。
A型晶体优选由醇或醚,特别是由异丙醚、丁醇或异丙醇中结晶得到。
A型晶体也可由这些溶剂的混合物,特别是由乙醇/异丙醚混合物中结晶得到。
B型晶体是相当特殊地由甲苯中结晶得到。
如果合适,可以通过向溶液中分别放入少量A型或B型种晶以引发得到预期的A型或B型晶体。
A型或B型晶体的分离是按照本领域技术人员已知的方法进行的。
式(Ⅰ)化合物的A型或B型晶型与在世界专利申请WO97/22169和WO95/35308中所述的无定形的化合物(Ⅰ)具有相同的治疗活性。
它们具有对ICE(白细胞介素-1β转化酶)的抑制活性,在治疗炎性、自身免疫和神经变性疾病方面特别有用。
因此,本发明的一个对象是作为药物的上述A型或B型晶体。
晶型A或B的式(Ⅰ)化合物可以通过口服、非肠道、局部施用、吸入或植入等方式使用。它们可以以按照常用方法制备的普通或糖衣药片、明胶胶囊、粒剂、栓剂、阴道药栓、注射制剂、膏剂、霜剂、凝胶、微球、植入剂、贴剂等形式使用。
A或B型的晶态式(Ⅰ)化合物可以与用于制备药物组合物的赋形剂、稀释剂和本领域技术人员了解的所有载体混合。作为常用于这些药物组合物中的赋形剂实例,可以提到以下物质:滑石,阿拉伯树胶、乳糖,淀粉,硬脂酸镁,可可脂,水基或非水载液,动物或植物来源的脂肪类物质,石蜡衍生物,二醇类,各种润湿剂、分散剂或乳化剂,防腐剂。
因此,本发明扩展到药物组合物,其中含有作为活性组分的至少一种如上定义的A型或B型式(Ⅰ)化合物和一种或多种可药用的赋形剂、稀释剂或载体。
本发明的又一对象是如上定义的A或B型晶态式(Ⅰ)化合物在制备用于抑制ICE(白细胞介素-1β转化酶)活性的药物中的应用。
以下实施例示例说明了本发明而并非是对它的限制。
实施例1:利用自正丁醇中结晶得到A型晶体。
将1.5ml正丁醇加到300mg无定形化合物Ⅰ(按照专利申请WO9722619中所述方法得到)中,在环境温度下将反应介质搅拌2小时15分。观察到产物结晶,将该产物分离并在20℃和4毫巴下干燥。得到160mg无水的式(Ⅰ)化合物(A型)。
实施例2:利用自异丙醇中结晶得到A型晶体。
将1.5ml异丙醇加到300mg无定形化合物Ⅰ(按照专利申请WO9722619中所述方法得到)中,将反应介质在环境温度下搅拌16小时,观察到产物结晶,分离出该产物并在20℃和4毫巴下干燥。得到166mg无水的式(Ⅰ)化合物(A型)。
实施例3:利用自甲苯中结晶得到B型晶体。
将1.5ml甲苯加到300mg无定形化合物Ⅰ(按照专利申请WO9722619中所述的方法得到)中,将反应介质在环境温度下搅拌16小时。观察到产物结晶,分离出该产物并在20℃和4毫巴下干燥。得到水合的式(Ⅰ)化合物(B型)。
实施例4:利用自异丙醚/乙醇混合物中结晶得到A型晶体。
在氮气和搅拌下将23.8ml无水乙醇加到11.9g无定形化合物(Ⅰ)中,将该悬浮液加热至60±2℃以得到溶液。将该溶液冷却到40±2℃,此时开始结晶并使溶液保持此温度1小时。然后在40±2℃下于15分钟内加入119ml异丙醚并使反应介质保持此温度15分钟,随后于15分钟内冷却到20±2℃,在这些条件下保持1小时,然后在15分钟内再冷却到0~+5℃,保持2小时。分离出反应介质,用异丙醚洗,在20℃下减压干燥12小时,得到11.3g无水的式(Ⅰ)化合物(A型)。
吸湿性曲线(或水吸收等温线)
吸水等温线是用DVS1型动态蒸汽吸收装置(SurfaceMeasurement System Ltd)在恒温和或多或少含水的氮气氛下得到的。气氛的相对湿度(RH)分步调节。当待分析的样品的重量已达到恒值时由某一步进行到下一步。
相对湿度(%) | 无定型 | 无水的A型 | 水合的B型 | |||
吸收 | 解吸 | 吸收 | 解吸 | 吸收 | 解吸 | |
0.012.021.032.043.051.057.066.075.080.090.096.0 | 0.000.670.971.291.601.832.032.372.903.715.115.93 | -0.201.482.092.582.943.193.353.613.904.124.945.93 | 0.000.030.050.070.090.110.130.140.140.160.140.06 | 0.110.120.140.190.210.220.210.210.210.210.190.06 | 0.001.412.363.233.884.264.534.925.275.455.936.86 | -0.111.422.333.143.754.134.404.755.085.305.966.86 |
在吸收循环期间A型不吸水(<0.2%)。将样品在相对湿度96%(温度32℃)的隔室内放置7天,证实了这种不吸温性。观察到水吸收率约为0.15%。水合型(B型)在同样条件下具较高的吸湿性(7%水)。这与无定形的情形相同。
Claims (16)
1.晶体形式的无水的1S-[1α(2S*,3R*),9α]-6,10-二氧代-N-(2-乙氧基-5-氧代-四氢-3-呋喃基)-9-[[(1-异喹啉基)羰基]氨基]八氢-6H-哒嗪并[1,2-a][1,2]二氮杂-1-甲酰胺(A型)。
2.根据权利要求1的晶体形式的无水1S-[1α(2S*,3R*),9α]-6,10-二氧代-N-(2-乙氧基-5-氧代-四氢-3-呋喃基)-9-[[(1-异喹啉基)羰基]氨基]八氢-6H-哒嗪并[1,2-a][1,2]二氮杂-1-甲酰胺(A型),它具有至少一个以下特征:
a)自168℃开始的吸热熔融峰,
b)红外光谱在大约以下位置有特征吸收(Nujol,cm-1):3253;1789;1702;1681;1644,
c)XR衍射图的特征点阵间距(d,)等于:17.73;8.87;8.11;7.50;7.17;6.31;6.09;5.81。
3.具有特征a、b和c的权利要求2中定义的结晶型无水1S-[1α(2S*,3R*),9α]-6,10-二氧代-N-(2-乙氧基-5-氧代-四氢-3-呋喃基)-9-[[(1-异喹啉基)羰基]氨基]八氢-6H-哒嗪并[1,2-a][1,2]二氮杂-1-甲酰胺(A型)。
4.权利要求2或3中定义的结晶型无水1S-[1α(2S*,3R*),9α]-6,10-二氧代-N-(2-乙氧基-5-氧代-四氢-3-呋喃基)-9-[[(1-异喹啉基)羰基]氨基]八氢-6H-哒嗪并[1,2-a][1,2]二氮杂-1-甲酰胺(A型),其红外光谱与图2A基本相同,XR衍射图与图3A基本相同。
5.晶体形式的水合的1S-[1α(2S*,3R*),9α]-6,10-二氧代-N-(2-乙氧基-5-氧代-四氢-3-呋喃基)-9-[[(1-异喹啉基)羰基]氨基]八氢-6H-哒嗪并[1,2-a][1,2]二氮杂-1-甲酰胺(B型)。
6.根据权利要求5的晶体形式的水合1S-[1α(2S*,3R*),9α]-6,10-二氧代-N-(2-乙氧基-5-氧代-四氢-3-呋喃基)-9-[[(1-异喹啉基)羰基]氨基]八氢-6H-哒嗪并[1,2-a][1,2]二氮杂-1-甲酰胺,它具有至少一个以下特征:
a)在50至110℃之间和110至130℃之间吸热脱水和自162℃开始的吸热熔化,
b)在以下位置有特征吸收的B型红外谱(Nujol,cm-1):3569;3447;3322;1778;1682;1660,
c)特征点阵间距(d,)如下的B型XR衍射图:11.34;10.80;10.06;7.59;7.16;6.71;6.41;6.11;5.44。
7.具有特征a、b和c的权利要求6中定义的结晶型水合1S-[1α(2S*,3R*),9α]-6,10-二氧代-N-(2-乙氧基-5-氧代-四氢-3-呋喃基)-9-[[(1-异喹啉基)羰基]氨基]八氢-6H-哒嗪并[1,2-a][1,2]二氮杂-1-甲酰胺(B型)。
8.权利要求6或7中定义的结晶型水合1S-[1α(2S*,3R*),9α]-6,10-二氧代-N-(2-乙氧基-5-氧代-四氢-3-呋喃基)-9-[[(1-异喹啉基)羰基]氨基]八氢-6H-哒嗪并[1,2-a][1,2]二氮杂-1-甲酰胺(B型),其红外光谱与图2B基本相同,XR衍射图与图3B基本相同。
9.制备权利要求1至8中任一项中定义的A型或B型晶体的方法,其特征在于,将无定形的1S-[1α(2S*,3R*),9α]-6,10-二氧代-N-(2-乙氧基-5-氧代-四氢-3-呋喃基)-9-[[(1-异喹啉基)羰基]氨基]八氢-6H-哒嗪并[1,2-a][1,2]二氮杂-1-甲酰胺在合适的有机溶剂或其混合物中混合,特别是在环境温度下混合,结晶后得到预期的A型或B型晶体。
10.根据权利要求9的制备A型晶体的方法,其特征在于,溶剂是醚,特别是异丙醚。
11.根据权利要求9的制备A型晶体的方法,其特征在于,溶剂是醇,特别是正丁醇或异丙醇。
12.根据权利要求9的制备A型晶体的方法,其特征在于,在醇和醚的混合物中,特别是在乙醇/异丙醚混合物中进行结晶。
13.根据权利要求9的制备B型晶体的方法,其特征在于,溶剂是甲苯。
14.权利要求1-8中定义的A或B型晶体作为药物。
15.含有至少一种权利要求13中定义的药物和一种或多种可药用的赋形剂、稀释剂或载体的药物组合物。
16.权利要求1-8中任一项中定义的晶体形式在制备用于抑制ICE(白细胞介素-1β转化酶)活性的药物中的应用。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR98/04367 | 1998-04-08 | ||
FR9804367A FR2777279B1 (fr) | 1998-04-08 | 1998-04-08 | Nouvelles formes cristallines du 1s-[1alpha(2s*,3r*), 9 alpha] 6,10-dioxo-n-(2-ethoxy-5-oxo-tetrahydro-3-furanyl) -9[[(1-isoquinolyl)carbonyl]amino]octohydro-6h-pyridazino [1,2-a][1,2]diazepine-1-carboxamide |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1305491A true CN1305491A (zh) | 2001-07-25 |
CN1202123C CN1202123C (zh) | 2005-05-18 |
Family
ID=9524993
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB998071455A Expired - Fee Related CN1202123C (zh) | 1998-04-08 | 1999-04-07 | 晶体形式的1S-[1α(2S<sup>*</sup>,3R<sup>*</sup>),9α]-6,10-二氧代-N-(2-乙氧基-5-氧代-四氢-3-呋喃基)-9-[[1-异喹啉基]羰基]氨基]八氢-6H-哒嗪并[1,2-A][1,2]二氮杂䓬-1-甲酰基 |
Country Status (38)
Country | Link |
---|---|
US (2) | US6544977B1 (zh) |
EP (1) | EP1070083B1 (zh) |
JP (1) | JP2002511485A (zh) |
KR (1) | KR100582981B1 (zh) |
CN (1) | CN1202123C (zh) |
AP (1) | AP1734A (zh) |
AR (1) | AR018328A1 (zh) |
AT (1) | ATE315044T1 (zh) |
AU (1) | AU758042B2 (zh) |
BG (1) | BG64736B1 (zh) |
BR (1) | BR9909549A (zh) |
CA (1) | CA2325629C (zh) |
CU (1) | CU23055A3 (zh) |
CZ (1) | CZ299744B6 (zh) |
DE (1) | DE69929315T2 (zh) |
DK (1) | DK1070083T3 (zh) |
EA (1) | EA002761B1 (zh) |
EE (1) | EE04467B1 (zh) |
ES (1) | ES2253880T3 (zh) |
FR (1) | FR2777279B1 (zh) |
GE (1) | GEP20032974B (zh) |
HK (1) | HK1038575B (zh) |
HR (1) | HRP20000665B1 (zh) |
HU (1) | HU227561B1 (zh) |
ID (1) | ID26290A (zh) |
IL (2) | IL138818A (zh) |
ME (1) | ME01627B (zh) |
NO (1) | NO327995B1 (zh) |
NZ (1) | NZ507199A (zh) |
PL (1) | PL197016B1 (zh) |
RS (1) | RS49916B (zh) |
SI (1) | SI1070083T1 (zh) |
SK (1) | SK286267B6 (zh) |
TR (1) | TR200002914T2 (zh) |
TW (1) | TW522152B (zh) |
UA (1) | UA71563C2 (zh) |
WO (1) | WO1999052935A1 (zh) |
ZA (1) | ZA200005438B (zh) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2396987T3 (es) * | 2006-06-30 | 2013-03-01 | Novartis Ag | Derivados de quinolina y sus composiciones farmacéuticas |
AU2014277867B2 (en) * | 2007-12-04 | 2016-11-03 | Arbutus Biopharma Corporation | Targeting lipids |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6204261B1 (en) * | 1995-12-20 | 2001-03-20 | Vertex Pharmaceuticals Incorporated | Inhibitors of interleukin-1β Converting enzyme inhibitors |
US5552400A (en) * | 1994-06-08 | 1996-09-03 | Sterling Winthrop Inc. | Fused-bicyclic lactams as interleukin-1β converting enzyme inhibitors |
-
1998
- 1998-04-08 FR FR9804367A patent/FR2777279B1/fr not_active Expired - Lifetime
-
1999
- 1999-03-15 TW TW088103966A patent/TW522152B/zh not_active IP Right Cessation
- 1999-03-30 AR ARP990101432A patent/AR018328A1/es active IP Right Grant
- 1999-04-07 TR TR2000/02914T patent/TR200002914T2/xx unknown
- 1999-04-07 JP JP2000543491A patent/JP2002511485A/ja active Pending
- 1999-04-07 AP APAP/P/2000/001939A patent/AP1734A/en active
- 1999-04-07 ID IDW20002015A patent/ID26290A/id unknown
- 1999-04-07 CN CNB998071455A patent/CN1202123C/zh not_active Expired - Fee Related
- 1999-04-07 WO PCT/FR1999/000799 patent/WO1999052935A1/fr active IP Right Grant
- 1999-04-07 SK SK1488-2000A patent/SK286267B6/sk not_active IP Right Cessation
- 1999-04-07 EA EA200001047A patent/EA002761B1/ru not_active IP Right Cessation
- 1999-04-07 DK DK99911890T patent/DK1070083T3/da active
- 1999-04-07 ME MEP-2000-608A patent/ME01627B/me unknown
- 1999-04-07 CU CU20000213A patent/CU23055A3/es unknown
- 1999-04-07 HU HU0101586A patent/HU227561B1/hu not_active IP Right Cessation
- 1999-04-07 AU AU30416/99A patent/AU758042B2/en not_active Ceased
- 1999-04-07 SI SI9930877T patent/SI1070083T1/sl unknown
- 1999-04-07 CA CA2325629A patent/CA2325629C/fr not_active Expired - Fee Related
- 1999-04-07 NZ NZ507199A patent/NZ507199A/xx not_active IP Right Cessation
- 1999-04-07 PL PL343350A patent/PL197016B1/pl unknown
- 1999-04-07 EE EEP200000586A patent/EE04467B1/xx unknown
- 1999-04-07 EP EP99911890A patent/EP1070083B1/fr not_active Expired - Lifetime
- 1999-04-07 DE DE69929315T patent/DE69929315T2/de not_active Expired - Lifetime
- 1999-04-07 ES ES99911890T patent/ES2253880T3/es not_active Expired - Lifetime
- 1999-04-07 GE GEAP19995614A patent/GEP20032974B/en unknown
- 1999-04-07 BR BR9909549-1A patent/BR9909549A/pt not_active Application Discontinuation
- 1999-04-07 KR KR1020007011159A patent/KR100582981B1/ko not_active IP Right Cessation
- 1999-04-07 US US09/647,858 patent/US6544977B1/en not_active Expired - Lifetime
- 1999-04-07 AT AT99911890T patent/ATE315044T1/de active
- 1999-04-07 CZ CZ20003678A patent/CZ299744B6/cs not_active IP Right Cessation
- 1999-04-07 RS YUP-608/00A patent/RS49916B/sr unknown
- 1999-07-04 UA UA2000116295A patent/UA71563C2/uk unknown
-
2000
- 2000-10-02 IL IL138818A patent/IL138818A/en not_active IP Right Cessation
- 2000-10-05 ZA ZA200005438A patent/ZA200005438B/en unknown
- 2000-10-06 BG BG104829A patent/BG64736B1/bg unknown
- 2000-10-06 NO NO20005060A patent/NO327995B1/no not_active IP Right Cessation
- 2000-10-09 HR HR20000665A patent/HRP20000665B1/xx not_active IP Right Cessation
-
2002
- 2002-01-07 HK HK02100107.8A patent/HK1038575B/zh not_active IP Right Cessation
- 2002-11-18 US US10/299,242 patent/US6946459B2/en not_active Expired - Lifetime
-
2005
- 2005-04-14 IL IL168047A patent/IL168047A/en not_active IP Right Cessation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1063181C (zh) | 作为药物的[r-(z)]-1-氮杂双环[2,2,1]庚-3-酮,0-[3-(3-甲氧基苯基)-2-丙炔基]-肟的马来酸盐 | |
CN112142679B (zh) | 一种吉非替尼与香草酸共晶甲醇溶剂合物及其制备方法 | |
CN1898211A (zh) | 喹啉化合物的晶形及其生产方法 | |
CN1633439A (zh) | 阿托伐他汀半钙脱溶剂的方法和基本上不含有机溶剂的阿托伐他汀半钙 | |
CN1714098A (zh) | β-L-2'-脱氧胸苷的结晶形及非晶形 | |
CN1202123C (zh) | 晶体形式的1S-[1α(2S<sup>*</sup>,3R<sup>*</sup>),9α]-6,10-二氧代-N-(2-乙氧基-5-氧代-四氢-3-呋喃基)-9-[[1-异喹啉基]羰基]氨基]八氢-6H-哒嗪并[1,2-A][1,2]二氮杂䓬-1-甲酰基 | |
CN1777586A (zh) | 稳定的无定形樟脑磺酸氨氯地平、其制备工艺以及其口服给药的组合物 | |
CN101068819A (zh) | 制备晶体大环内酯类的方法 | |
CN1309413C (zh) | 四肽衍生物的晶体 | |
CN1874993B (zh) | 莫达芬尼组合物 | |
US20060154953A1 (en) | Amorphous tacrolimus and preparation thereof | |
CN1221527C (zh) | 茋衍生物的新型结晶及其制造方法 | |
CN1293055C (zh) | 哌啶衍生物晶体、其制备所用的中间体以及其制备方法 | |
CN1136201C (zh) | 药理活性的对映体及其制备方法 | |
CN1257478A (zh) | 用作抗-心律不齐药物的硝基苯甲酰胺 | |
CN1980888B (zh) | 莫达芬尼组合物 | |
CN116874488A (zh) | 甲磺酸普依司他i晶型及其制备方法和用途 | |
CN1675173A (zh) | 毒蕈碱激动剂 | |
CN1886419A (zh) | 3β-氨基-17-亚甲基-雄甾烷-6α,7β-二醇盐酸盐的晶形 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
CF01 | Termination of patent right due to non-payment of annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20050518 Termination date: 20180407 |